Graziano Seghzzi, Managing Partner of Sofinnova Partners, said: "Building on the success of Biovelocita I in Italy, we have now developed a pan-European strategy and assembled a world class team to ...

Divcon, a leader in building management systems (BMS) and electrical power monitoring systems (EPMS) for mission-critical facilities, has launched Divcon Pulse - a web-based platform designed to ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Shockwaves of fun &ME, a trailblazer in electronic music, is set to deliver an electrifying night of deep house and tech ...

Bristol Motor Speedway opened its “Major League Year” in grand fashion Wednesday with some of the fastest racers in both ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

South Korean battery supplier SK On is looking at a different type of cooling method for electric vehicle battery packs. Last ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...